Results 91 to 100 of about 32,821 (278)
American Journal of Hematology, EarlyView.9% of patients with multiple myeloma achieve 15‐year progression‐free survival; Kaplan‐Meier curves for PFS (A) and OS (B). ABSTRACT The therapeutic advances during the last two decades have rendered multiple myeloma a chronic disease and, thus, it is important to identify patient subgroups which may have extremely favorable outcomes and optimize their
Meletios A. Dimopoulos +17 more
wiley +1 more source
Antibody fragments as probe in biosensor development [PDF]
, 2008 Today's proteomic analyses are generating increasing numbers of biomarkers, making it essential to possess highly specific probes able to recognize those targets.
Bonroy, Kristien +3 more
core +3 more sources
Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities
Arthritis &Rheumatology, EarlyView.Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley +1 more source
Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy [PDF]
, 2015 licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
Achilefu, Samuel +8 more
core +2 more sources
Arthritis &Rheumatology, Accepted Article.Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens +14 more
wiley +1 more source
B cells and systemic sclerosis interstitial lung disease
Arthritis &Rheumatology, Accepted Article.Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman +2 more
wiley +1 more source
Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. [PDF]
Front Immunol, 2022 Hambach J +3 more
europepmc +1 more source
Structural insights and biomedical potential of IgNAR scaffolds from sharks [PDF]
, 2014 Peer reviewedPublisher ...
Barelle, Caroline +5 more
core +1 more source
Engineering antibodies with cancer‐associated binding sites
BMEMat, EarlyView.This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian +4 more
wiley +1 more source
STAR Protocols, 2022 Summary: Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources.
Danqing Li +8 more
doaj